Literature DB >> 11320088

Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization.

K M Smith1, R A Van Etten.   

Abstract

c-Abl is a non-receptor tyrosine kinase that is activated in human leukemias by the fusion of Bcr or Tel sequences to the Abl NH(2) terminus. Although Bcr and Tel have little in common, both contain oligomerization domains. To determine whether oligomerization alone is sufficient to activate c-Abl, we have generated and characterized an Abl protein that can be activated selectively with the chemical inducer of dimerization, AP1510. Mutant Abl proteins with one (c4F1) or two (c4F2) copies of the AP1510 binding motif (FKBP) transformed NIH 3T3 cells in a ligand-dependent manner with the c4F2 protein 60-fold more potent than c4F1. Both chimeric proteins exhibited ligand-dependent dimerization in vivo, suggesting that the increased transformation efficiency of the c4F2 mutant reflects more effective dimerization rather than formation of higher order oligomers. In the absence of ligand, c4F2-expresssing fibroblasts morphologically reverted and arrested in G(1). In Ba/F3 cells, the c4F2 chimera exhibited ligand-dependent kinase activation, transformation to interleukin 3-independent growth, and relocalization of the fusion protein from nucleus to cytoplasm. These results demonstrate that dimerization alone is sufficient to activate the Abl kinase and provide a method to regulate conditionally c-Abl activity that will be useful for studying the normal physiological role of c-Abl and the mechanism of transformation and leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11320088     DOI: 10.1074/jbc.M100786200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Abl tyrosine kinase promotes dorsal ruffles but restrains lamellipodia extension during cell spreading on fibronectin.

Authors:  Hua Jin; Jean Y J Wang
Journal:  Mol Biol Cell       Date:  2007-08-08       Impact factor: 4.138

2.  Brought to life: targeted activation of enzyme function with small molecules.

Authors:  Anthony C Bishop; Vincent L Chen
Journal:  J Chem Biol       Date:  2008-09-20

3.  Structural insights into the tyrosine phosphorylation-mediated inhibition of SH3 domain-ligand interactions.

Authors:  Balázs Merő; László Radnai; Gergő Gógl; Orsolya Tőke; Ibolya Leveles; Kitti Koprivanacz; Bálint Szeder; Metta Dülk; Gyöngyi Kudlik; Virág Vas; Anna Cserkaszky; Szabolcs Sipeki; László Nyitray; Beáta G Vértessy; László Buday
Journal:  J Biol Chem       Date:  2019-01-18       Impact factor: 5.157

4.  Quantifying membrane protein oligomerization with fluorescence cross-correlation spectroscopy.

Authors:  Megan J Kaliszewski; Xiaojun Shi; Yixuan Hou; Ryan Lingerak; Soyeon Kim; Paul Mallory; Adam W Smith
Journal:  Methods       Date:  2018-02-13       Impact factor: 3.608

Review 5.  ABL tyrosine kinases: evolution of function, regulation, and specificity.

Authors:  John Colicelli
Journal:  Sci Signal       Date:  2010-09-14       Impact factor: 8.192

6.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

7.  Activation of abl family kinases in solid tumors.

Authors:  Sourik S Ganguly; Rina Plattner
Journal:  Genes Cancer       Date:  2012-05

Review 8.  Structure and dynamic regulation of Abl kinases.

Authors:  Shoghag Panjarian; Roxana E Iacob; Shugui Chen; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2013-01-11       Impact factor: 5.157

9.  Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.

Authors:  Cristina E Tognon; Cameron D Mackereth; Aruna M Somasiri; Lawrence P McIntosh; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

10.  A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Authors:  Ryan P Million; Nari Harakawa; Sergei Roumiantsev; Lyuba Varticovski; Richard A Van Etten
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.